Peptides for Muscle Growth in Australia (Research)

Direct answer: what are these compounds and are they approved in Australia?

The phrase peptides for muscle growth is a popular search term that usually points to a class of research compounds acting on the growth hormone (GH) and insulin-like growth factor 1 (IGF-1) axis. In the scientific literature these are described as growth hormone secretagogues, growth-hormone-releasing hormone (GHRH) analogues and growth-hormone-releasing peptides (GHRPs). The term muscle growth is the common label people use, but it does not describe an approved outcome for these compounds in humans.

In Australia most of these substances are Schedule 4 (prescription-only) under the Poisons Standard and are not registered on the Australian Register of Therapeutic Goods (ARTG) for general supply for this purpose. Several are also listed by the World Anti-Doping Agency (WADA) under category S2. They cannot lawfully be supplied for human use without appropriate authorisation.

NovaPeptides supplies compounds in this category for laboratory research use only. This article summarises what the literature studies about this group of molecules and does not provide dosing, protocols or any suggestion of personal use.

What this compound class actually is

The compounds grouped under peptides for muscle growth are not a single drug. They are a family of molecules that interact, in different ways, with the body's own growth hormone signalling system. Rather than being growth hormone itself, most of them are studied as agents that influence how the pituitary gland releases GH.

Compounds commonly discussed in this class

• GHRH analogues such as sermorelin, tesamorelin and CJC-1295
• Growth-hormone-releasing peptides (GHRPs) such as GHRP-2 and GHRP-6
• Other growth hormone secretagogues such as ipamorelin
• Non-peptide secretagogues of the MK-677 (ibutamoren) class studied as orally active ghrelin-receptor agonists

Each of these has its own individual research profile. This page is a hub that sits above the single-compound reference pages, giving context for how they relate to one another before you read about any one molecule in detail.

The GH and IGF-1 axis in plain terms

Growth hormone secretion is governed by the hypothalamus and pituitary gland. The hypothalamus releases GHRH, which stimulates the pituitary to secrete GH, while a second hormone, somatostatin, acts as a brake. A third signal, ghrelin, also stimulates GH release through a separate receptor. GH is released in pulses rather than at a constant level.

Once GH enters the circulation, many of its downstream effects are mediated by IGF-1, which is produced largely by the liver in response to GH. Together GH and IGF-1 form what researchers call the GH to IGF-1 axis, one of the neuroendocrine systems studied in relation to growth, tissue development and metabolism. The compounds in this class are of research interest because they act at different points on this axis.

GHRH analogues versus GHRPs and secretagogues

A key distinction in the literature is the mechanism by which a compound acts. GHRH analogues are structural relatives of the body's own GHRH and bind the GHRH receptor on the pituitary. Sermorelin, tesamorelin and CJC-1295 are discussed in this group. Research has explored chemical modifications intended to extend how long these molecules remain active.

GHRPs and other secretagogues act through a different route. They work largely at the ghrelin receptor and are studied for the way they can also reduce the inhibitory effect of somatostatin. GHRP-2, GHRP-6 and ipamorelin are described in this group, while MK-677-class compounds are studied as orally active, non-peptide agents acting on the same receptor.

Because the two routes are complementary in the scientific models, the literature frequently examines them side by side. This mechanistic difference, not any claimed real-world result, is the main reason the individual compounds are described as distinct.

What the research actually shows (and its stage)

Across this class the research stage varies considerably and much of it is preclinical or early experimental. Some compounds have been investigated in clinical settings for specific, narrow medical questions unrelated to general muscle outcomes, while others remain largely confined to laboratory and animal studies. It is important not to generalise findings from one compound, or from one narrow clinical context, to the whole class.

Published work in this area typically reports on how a compound interacts with its target receptor, how it influences measured GH or IGF-1 levels in study models, its pharmacokinetics and its detectability. These are mechanistic and analytical endpoints. They are not statements that any compound builds muscle, improves body composition or enhances performance in people, and no such claim is made here.

Australian regulatory and TGA status

In Australia the Therapeutic Goods Administration administers the Poisons Standard, which schedules substances according to how they may be accessed. Growth hormone secretagogues, GHRH analogues and GH-releasing peptides, including named compounds such as ipamorelin, CJC-1295, sermorelin, tesamorelin, GHRP-2 and GHRP-6, are generally captured as Schedule 4 (prescription-only) substances.

Schedule 4 status means a substance requires a prescription and appropriate authorisation, and it is an offence to supply or import it for human use without that authorisation. Importantly, being scheduled is not the same as being approved: these compounds are not registered on the ARTG for use as muscle-growth agents, and no such approval should be assumed or implied.

Key points on Australian status

• Generally Schedule 4 (prescription-only) under the Poisons Standard
• Not ARTG-registered for a muscle-growth indication
• Supply or import for human use without authorisation is unlawful
• State and territory laws may add further requirements

WADA and the anti-doping angle for athletes

Athletes subject to anti-doping rules should be aware that this entire class is addressed by the World Anti-Doping Agency. Under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), WADA lists GHRH and its analogues such as CJC-1295, sermorelin and tesamorelin; growth hormone secretagogues and mimetics such as ibutamoren (MK-677) and ipamorelin; and GH-releasing peptides such as GHRP-2 and GHRP-6.

This prohibition applies at all times, both in and out of competition, and the substances are understood to be detectable in sport testing. Any athlete bound by anti-doping rules should consult the current WADA Prohibited List and their sport's governing body before any involvement with compounds in this class.

Research use only: how Nova supplies these compounds

NovaPeptides lists compounds in this category strictly for laboratory and research purposes. That framing is deliberate and reflects the regulatory reality above: these are not consumer products, not approved therapies for muscle growth and not supplied with any human-use instructions.

For that reason you will not find dosing, administration guidance, protocols or outcome promises anywhere on this hub or on the individual compound pages. The role of these pages is to summarise what the scientific literature investigates, in neutral terms, so that researchers can locate accurate background information.

How the individual compounds relate, and where to read more

Because the compounds in this class act on the same axis through complementary mechanisms, the literature often groups and compares them. GHRH analogues (sermorelin, tesamorelin, CJC-1295) sit on one side, GHRPs and secretagogues (GHRP-2, GHRP-6, ipamorelin) on another, and non-peptide secretagogues of the MK-677 class form a further distinct group.

If you want detail on a specific molecule, the single-compound reference pages cover each one individually, including its mechanism, research stage and regulatory notes. This hub is the starting point that places each of them in context within the broader GH to IGF-1 research picture.

Groupings at a glance

• GHRH analogues: sermorelin, tesamorelin, CJC-1295
• GHRPs and peptide secretagogues: GHRP-2, GHRP-6, ipamorelin
• Non-peptide secretagogues: MK-677 (ibutamoren) class

Frequently asked questions